• If you are wondering whether Abbott Laboratories at around US$101.56 is offering value or just noise, it helps to step back and look at the full picture on price versus fundamentals.
• The stock is down 1.9% over the last week, 7.6% over the last month, and 20.1% over the past year, which may lead some investors to reassess both its growth potential and perceived risk.
• Recent headlines around Abbott have focused on its ongoing role in the medical devices and diagnostics space, with attention on how its product portfolio positions it within the broader healthcare sector. This context has kept investor interest alive even as the share price has moved lower over multiple time frames.
• Right now, Abbott holds a valuation score of 5 out of 6, which reflects results across a set of standard valuation checks. The next sections will walk through those methods and then introduce a way to look at valuation that goes beyond any single model.

Approach 1: Abbott Laboratories Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting its future cash flows and discounting them back to the present.

For Abbott Laboratories, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about $7.26b. Analyst and extrapolated projections from Simply Wall St then extend this, with free cash flow estimates such as $9.16b in 2026 and $9.997b in 2027, reaching a projected $14.42b in 2035.

After discounting these future cash flows, the DCF model arrives at an estimated intrinsic value of $132.24 per share. Compared with the recent share price of about $101.56, this implies the stock is around 23.2% undervalued on these assumptions.

This model suggests that, based purely on projected cash generation and the discount rate applied, Abbott Laboratories currently trades at a discount to its calculated value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Abbott Laboratories is undervalued by 23.2%. Track this in your watchlist or portfolio, or discover 60 more high quality undervalued stocks.

Approach 2: Abbott Laboratories Price vs Earnings

For profitable companies, the P/E ratio is a straightforward way to connect what you pay for the stock with what the business is currently earning. It lets you see how many dollars of price you are paying for each dollar of earnings today.

What counts as a “normal” P/E really depends on how the market views a company’s growth potential and risk. Higher expected growth or lower perceived risk can support a higher P/E, while slower expected growth or higher risk usually points to a lower one.

Abbott Laboratories is trading on a P/E of 27.21x, compared with the Medical Equipment industry average of about 26.54x and a peer group average of 38.97x. Simply Wall St’s Fair Ratio for Abbott is 36.18x, which is a proprietary estimate of what the P/E might be given factors such as earnings growth, industry, profit margins, market cap and company specific risks.

This Fair Ratio approach can be more informative than simple peer or industry comparisons because it adjusts for company characteristics rather than assuming one size fits all. Since Abbott’s current P/E of 27.21x sits below the Fair Ratio of 36.18x, the shares screen as undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Abbott Laboratories Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so meet Narratives, a simple tool on Simply Wall St’s Community page that lets you link your view of Abbott Laboratories’ story to a set of numbers. It pairs your assumptions for fair value, future revenue, earnings and margins with a forecast, then compares that fair value to today’s price. It updates automatically as news or earnings arrive and allows, for example, one investor who focuses on Abbott’s diversified healthcare footprint to build a higher fair value than another investor who is more focused on risks such as premium valuation or regulatory pressure, even though both are looking at the same company.

Do you think there's more to the story for Abbott Laboratories? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.